Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antiplatelet resistance in Fontaine II peripheral arterial disease
NL-OMON53864Recruiting
- Sponsor
- Haaglanden Medical Centre
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of clopidogrel in arteriosclerosis obliterans (2 arms), sponsored by Haaglanden Medical Centre. Primary endpoints: Composite clinical endpoint and Antiplatelet resistance assessment. Started Sep 2024; status: recruiting.
02
Drugs
clopidogrel
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on NL-OMON53864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53864.